News
-
Quotient Receives Final Patent Approval For Its Enterion Technology – The Industry’s Leading Clinical Technology For Investigating Drug Absorption
5/1/2012
Quotient Clinical, part of Quotient Bioresearch (“Quotient”) announced today that it has received approval of the final patent for its Enterion technology. This completes a portfolio of eight granted patents across North America and Europe, with a lifetime extending through to 2020.
-
AstraZeneca To Acquire Ardea Biosciences For $1.26B Including Lead Product Lesinurad In Phase III Development For Gout
4/23/2012
AstraZeneca and Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.
-
Idaho Technology To Highlight Diagnostic FilmArray® Respiratory Panel At 28th Annual Clinical Virology Symposium
4/19/2012
Idaho Technology, Inc., a privately held clinical diagnostics company dedicated to providing the world's fastest, highest-quality instruments for pathogen identification and DNA analysis, today announced several posters will be presented highlighting its FilmArray® Respiratory Panel (FilmArray RP), a user-friendly Multiplex pathogen detection system, at the 28th Annual Clinical Virology Symposium and Annual Meeting of the Pan American Society for Clinical Virology, held April 22 - 25, 2012, in Daytona Beach, FL
-
AstraZeneca And Amgen Announce Collaboration To Jointly Develop And Commercialise Clinical-Stage Inflammation Portfolio
4/4/2012
AstraZeneca and Amgen recently announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).
-
Shire Announces Top-Line Results Of The PREVENT2 Trial
4/2/2012
Shire plc., the global specialty biopharmaceutical company, recently announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis.1
-
Lubiprostone Meets Primary Endpoint In Phase 3 Clinical Trial For Opioid-Induced Bowel Dysfunction (OBD)
2/3/2012
Sucampo Pharmaceuticals, Inc. (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced recently that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
-
Kedem Pharmaceuticals Engages A FDA Compliant Contract Formulation Development Company For The Production Of KDM-1102 Clinical Materials
1/5/2012
Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that it has signed a contract with a GMP pharmaceutical FDA compliant formulation development company, Corealis Pharma, Inc. for the production of the phase I clinical supplies of KDM-1102, the Company's second lead therapeutic drug.
-
Virginia G. Piper Cancer Center & TGen Form Drug Development Collaboration With Cedars-Sinai
11/10/2011
The Virginia G. Piper Cancer Center at Scottsdale Healthcare is expanding its efforts to accelerate advances in cancer care with the addition of Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute in Los Angeles as a collaborator in clinical trials to develop personalized therapies that could lead to more effective cancer treatments.
-
World Precision Instruments Launches Cell Tester - Unique Cell Biology Tool To Sense Stress And Stretch In Individual Cells
11/2/2011
World Precision Instruments Inc recently announced the launch of the new Cell Tester, a novel cell biology research tool, set to revolutionize the emerging field of ‘mechano transduction’ by allowing researchers to study the influence of mechanical force, stress or strain on cells and how these cells react to stimuli.
-
Novartis Achieves Strong Third Quarter Financial Performance And Pipeline Progress
10/28/2011
Novartis is announcing recently additional cost reduction activity, which will be executed over three to five years. Elements of the activity to include: reallocation of production within the Novartis network resulting in closure of two sites in Switzerland and one in Italy; restructuring the development organization largely in Switzerland and the US and relocating some research activities from Switzerland to the US.